GMO US Value ETF (GMOV) seeks to provide long-term capital appreciation by investing in undervalued U.S. stocks using GMO's proprietary quantitative value methodology. This actively managed value ETF targets companies trading below their estimated intrinsic worth based on fundamental analysis and mean-reversion principles.
How It Works
GMOV employs GMO's active, research-driven approach combining quantitative screening with fundamental analysis to identify undervalued U.S. equities across all market capitalizations. The fund uses proprietary valuation models incorporating price-to-book, price-to-earnings, and cash flow metrics while avoiding traditional value traps. Portfolio construction emphasizes risk management through diversification across sectors and market caps, with rebalancing driven by valuation changes rather than fixed schedules.
Key Features
- Managed by GMO, renowned for contrarian value investing and 7-year asset bubble forecasting with strong long-term track record
- Zero expense ratio structure makes it one of the most cost-effective actively managed value ETFs available
- Launched October 2024, representing GMO's first ETF offering of their institutional value strategy to retail investors
Risks
- This ETF can lose value if value investing continues underperforming growth strategies, as seen during 2010-2020 technology dominance periods
- Active management risk means the fund could underperform passive value ETFs if GMO's stock selection proves incorrect
- Value stocks typically decline 35-50% during market downturns and may take years to recover, requiring patient investors
Who Should Own This
Best suited for patient, contrarian investors with 5+ year time horizons seeking active value exposure as 10-25% satellite allocation. Medium-to-high risk tolerance required given value volatility and active management uncertainty. Ideal for investors believing in mean reversion and willing to endure extended underperformance periods.